Sprint Bioscience: Our Q4 comment - Redeye

Redeye comments on Sprint’s Q4 2021 report, representing a relatively calm quarter on the news front. We judge the company is in a solid financial position, and new licensing deals for the currently marketed VADA and DISA programs could materialize in 2022 and 2023. The company is looking to increase its number of employees and facility space during the coming years. While this will likely increase expenses, we judge it will facilitate the development of more new projects (new goal ~1.5 new projects/year) that will diversify Sprint’s income streams once out-licensed. We reiterate our positive view.

Länk till analysen i sin helhet: https://www.redeye.se/research/833124/sprint-bioscience-our-q4-comment?utm_source=finwire&utm_medium=RSS